Where Will Novavax Be in 3 Years?
As the hottest vaccine stock du jour, Novavax (NASDAQ: NVAX) has a long and bright future ahead. Thanks to its coronavirus jab, which was recently awarded an Emergency Use Authorization (EUA) by regulators in the U.S., the company's fortunes are improving rapidly in ways they've never attained before.
But its share price hasn't followed with an upward trajectory; in the last 12 months, Novavax stock collapsed by more than 73% despite a smorgasbord of global approvals for its vaccine and a constant drumbeat of new purchase orders from governments.
Will the vaccine maker manage to pull through for its shareholders over the next three years, or is its time in the limelight already drawing to a close?
Source Fool.com
